Molecular pathology as the driving force for personalized oncology

Maja H. Oktay, Pei Hui

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Innovative Tissue-Based Diagnostics Philadelphia, PA, USA, 4-5 June 2012 This article focuses on the current and emerging molecular diagnostics relevant to clinical practice of oncology discussed in the session of Molecular Pathology as the Driving Force for Personalized Oncology, one of the three main themes of innovative tissue-based diagnostics with the other two being pathology in cancer drug development, and in vivo microscopy and intraoperative imaging. The session brought together seven topics and a keynote presentation in the area of precision cancer diagnosis and treatment: single gene molecular testing as the most popular cancer molecular diagnostics in current time, panel gene mutation analysis as an emerging theme for cancer therapy targeting at multiple signaling pathways, and the next-generation sequencing platform - an ultimate molecular analysis of cancer for future clinical practice. Novel tactics based on existing technology were emphasized including in vitro drug sensitivity testing and exploring immunohistochemistry in combination with histocytological assays for risk assessment of tumor metastasis and layered immunohistochemistry to predict tumor response to target cancer treatment. Clinical molecular assay development, verification and validation were among practical topics in molecular diagnostic operations. The conference was culminated by Marc Ladanyi's keynote presentation of the current and future strategies for comprehensive routine clinical genotyping of lung cancers for optimal selection of targeted therapies.

Original languageEnglish (US)
Pages (from-to)811-813
Number of pages3
JournalExpert Review of Molecular Diagnostics
Volume12
Issue number8
DOIs
StatePublished - Nov 2012

Fingerprint

Molecular Pathology
Neoplasms
Immunohistochemistry
Medical Oncology
Therapeutics
Pharmaceutical Preparations
Genes
Lung Neoplasms
Pathology
Neoplasm Metastasis
Technology
Mutation

Keywords

  • molecular testing
  • personalized oncology

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

Molecular pathology as the driving force for personalized oncology. / Oktay, Maja H.; Hui, Pei.

In: Expert Review of Molecular Diagnostics, Vol. 12, No. 8, 11.2012, p. 811-813.

Research output: Contribution to journalArticle

@article{694ad395e0f44141a22d310eff767015,
title = "Molecular pathology as the driving force for personalized oncology",
abstract = "Innovative Tissue-Based Diagnostics Philadelphia, PA, USA, 4-5 June 2012 This article focuses on the current and emerging molecular diagnostics relevant to clinical practice of oncology discussed in the session of Molecular Pathology as the Driving Force for Personalized Oncology, one of the three main themes of innovative tissue-based diagnostics with the other two being pathology in cancer drug development, and in vivo microscopy and intraoperative imaging. The session brought together seven topics and a keynote presentation in the area of precision cancer diagnosis and treatment: single gene molecular testing as the most popular cancer molecular diagnostics in current time, panel gene mutation analysis as an emerging theme for cancer therapy targeting at multiple signaling pathways, and the next-generation sequencing platform - an ultimate molecular analysis of cancer for future clinical practice. Novel tactics based on existing technology were emphasized including in vitro drug sensitivity testing and exploring immunohistochemistry in combination with histocytological assays for risk assessment of tumor metastasis and layered immunohistochemistry to predict tumor response to target cancer treatment. Clinical molecular assay development, verification and validation were among practical topics in molecular diagnostic operations. The conference was culminated by Marc Ladanyi's keynote presentation of the current and future strategies for comprehensive routine clinical genotyping of lung cancers for optimal selection of targeted therapies.",
keywords = "molecular testing, personalized oncology",
author = "Oktay, {Maja H.} and Pei Hui",
year = "2012",
month = "11",
doi = "10.1586/erm.12.121",
language = "English (US)",
volume = "12",
pages = "811--813",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Molecular pathology as the driving force for personalized oncology

AU - Oktay, Maja H.

AU - Hui, Pei

PY - 2012/11

Y1 - 2012/11

N2 - Innovative Tissue-Based Diagnostics Philadelphia, PA, USA, 4-5 June 2012 This article focuses on the current and emerging molecular diagnostics relevant to clinical practice of oncology discussed in the session of Molecular Pathology as the Driving Force for Personalized Oncology, one of the three main themes of innovative tissue-based diagnostics with the other two being pathology in cancer drug development, and in vivo microscopy and intraoperative imaging. The session brought together seven topics and a keynote presentation in the area of precision cancer diagnosis and treatment: single gene molecular testing as the most popular cancer molecular diagnostics in current time, panel gene mutation analysis as an emerging theme for cancer therapy targeting at multiple signaling pathways, and the next-generation sequencing platform - an ultimate molecular analysis of cancer for future clinical practice. Novel tactics based on existing technology were emphasized including in vitro drug sensitivity testing and exploring immunohistochemistry in combination with histocytological assays for risk assessment of tumor metastasis and layered immunohistochemistry to predict tumor response to target cancer treatment. Clinical molecular assay development, verification and validation were among practical topics in molecular diagnostic operations. The conference was culminated by Marc Ladanyi's keynote presentation of the current and future strategies for comprehensive routine clinical genotyping of lung cancers for optimal selection of targeted therapies.

AB - Innovative Tissue-Based Diagnostics Philadelphia, PA, USA, 4-5 June 2012 This article focuses on the current and emerging molecular diagnostics relevant to clinical practice of oncology discussed in the session of Molecular Pathology as the Driving Force for Personalized Oncology, one of the three main themes of innovative tissue-based diagnostics with the other two being pathology in cancer drug development, and in vivo microscopy and intraoperative imaging. The session brought together seven topics and a keynote presentation in the area of precision cancer diagnosis and treatment: single gene molecular testing as the most popular cancer molecular diagnostics in current time, panel gene mutation analysis as an emerging theme for cancer therapy targeting at multiple signaling pathways, and the next-generation sequencing platform - an ultimate molecular analysis of cancer for future clinical practice. Novel tactics based on existing technology were emphasized including in vitro drug sensitivity testing and exploring immunohistochemistry in combination with histocytological assays for risk assessment of tumor metastasis and layered immunohistochemistry to predict tumor response to target cancer treatment. Clinical molecular assay development, verification and validation were among practical topics in molecular diagnostic operations. The conference was culminated by Marc Ladanyi's keynote presentation of the current and future strategies for comprehensive routine clinical genotyping of lung cancers for optimal selection of targeted therapies.

KW - molecular testing

KW - personalized oncology

UR - http://www.scopus.com/inward/record.url?scp=84871278946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871278946&partnerID=8YFLogxK

U2 - 10.1586/erm.12.121

DO - 10.1586/erm.12.121

M3 - Article

C2 - 23249199

AN - SCOPUS:84871278946

VL - 12

SP - 811

EP - 813

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 8

ER -